Correction: Current status of human biomonitoring of beauvericin and enniatins - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Correction: Updated overview of human biomonitoring for beauvericin and enniatins

  • By

  • Gisela H. Degen

  • Anamarija Romac

  • November 13, 2026

Share

  • 1

    A correction notice was issued for the article “Updated overview of human biomonitoring for beauvericin and enniatins.”.

  • 2

    The first author’s name was misspelled as “Gsela H. Degen”; the correct name is Gisela H. Degen.

  • 3

    In Table 2, the second-line entry in the final column, headed “Kyei et al. 2026,” was reported incorrectly.

  • 4

    The incorrect Table 2 entry was “9191.7%.”.

  • 5

    The corrected Table 2 entry is “91.7% > LOQ.”.

Original Source(s)

Correction: Current status of human biomonitoring of beauvericin and enniatins

  • by Gisela H. Degen, Anamarija Romac

  • November 13, 2026

Related Content

AI – Train with the best

Drawing before counting: causal diagrams and g-methods in critical care evidence synthesis

FDA flags vision loss risk with GLP-1 drugs

Analysis found higher rates of a rare optic nerve condition, prompting new warnings across the drug class.